NCT00264927已完成3 期
A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 77
- 试验地点
- 11
- 主要终点
- Serum sodium
研究概览
简要总结
To assess the efficacy of SR121463B in correcting hyponatremia in patients with syndrome of inappropriate antidiuretic secretion (SIADH).To assess the long-term efficacy of SR121463B in maintaining normal levels of serum sodium in patients with SIADH. To assess the safety and tolerability of SR121463B in patients with SIADH.
The double blind period is followed by an open label extension study with flexible doses of satavaptan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 years and higher.
- •SIADH (the diagnosis of SIADH is based on several criteria including true serum hypoosmolality, inappropriate urinary osmolality, clinical euvolemia, elevated urinary sodium excretion while on normal salt and water intake, and normal renal, adrenal, and thyroid functions: drug induced SIADH will be limited to carbamazepine or derivatives and antidepressants in patients in whom these drugs cannot be discontinued or easily replaced by other drugs)
- •Serum sodium between 115 and 132 mmol/L (at least two consecutive serum sodium levels of at least 24 hours apart, from Day -6 to Day -1); for sodium levels between 125 and 132 mmol/L, the spontaneous serum sodium increase between the two assessments on Day -1 should be < 4 mmol/L
- •Urinary osmolality >200mOsm/kg H2O
- •Urinary sodium > 30 mmol/L
排除标准
- •Patients with acute postoperative SIADH
- •Presence of dilutional hyponatremia in hypervolemic states such as congestive heart failure and liver disease with ascites
- •Presence of signs of hypovolemia (e.g., orthostatic hypotension, increased serum urea nitrogen, increased serum albumin, increased hematocrit, ...)
- •Administration of other V2 receptor antagonists or demeclocycline or lithium within one month, thiazides diuretics or spironolactone within 15 days, and urea or loop diuretics within two days prior to study drug administration
- •Patients with known treated or untreated adrenal deficiency
- •Presence of untreated hypothyroidism
- •Presence of uncontrolled diabetes with fasting glycemia > 200 mg/dL (> 11.09 mmol/L)
- •Presence of clinical and/or electrocardiographical signs of acute myocardial infarction or acute ischemia, or nay other clinically significant abnormality according to the Investigator on a 12 lead ECG recording
- •Administration of inducers of CYP3A4, phenytoin, rifampin, Saint John's Wort) or potent and moderate inhibitor so CYP3A4within two weeks prior to study drug administration
- •Inadequate hematological, renal and hepatic functions: hemoglobin (Hb) < 9 g/dl, neutrophils < 1,500/mm3, platelets <100,00/mm3, serum creatine>175 µmol/L, ALT and /or AST >2x upper limit of normal
- •QTcB > 500 ms
- •Serum potassium > 5 mmol/L
结局指标
主要结局
Serum sodium
次要结局
- Urinary and serum osmolality, free water clearance, urinary volume, urinary electrolytes, weight, thirst,
- Safety: Physical examination, vital signs, adverse events, ECG, hematology, serum chemistry
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
DILIPO (DILutIonal HyPOnatremia)Congestive Heart FailureNCT00274326Sanofi150
已完成
3 期
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionInappropriate ADH SyndromeHyponatremiaNCT00264914Sanofi57
已完成
不适用
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyNCT01049399Noscira SA146
Unknown
2 期
Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaNon-hypovolemic Non-acute HyponatremiaNCT01507727Jiangsu HengRui Medicine Co., Ltd.240
进行中（未招募）
不适用
THE BALANCE study: Treatment of Hyponatremia based on Lixivaptan in NYHA class III/IV Cardiac Patient Evaluation - CK-LX3401Hyponatremia in NYHA Class III/IV Cardiac PatientMedDRA version: 9.1Level: LLTClassification code 10021036Term: HyponatraemiaEUCTR2006-002567-62-ITCARDIOKINE BIOPHARMA, LLC650